Bio-Techne Corp [TECH] stock prices are up 2.19% to $49.85 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TECH shares have gain 4.01% over the last week, with a monthly amount glided 0.10%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bio-Techne Corp [NASDAQ: TECH] stock has seen the most recent analyst activity on May 30, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $59. Previously, KeyBanc Capital Markets downgraded its rating to Sector Weight on April 09, 2025. On March 18, 2025, Evercore ISI initiated with a Outperform rating and assigned a price target of $75 on the stock. Robert W. Baird downgraded its rating to a Neutral and decreased its price target to $68 on February 19, 2025. Citigroup downgraded its rating to a Neutral but $85 remained the price target by the analyst firm on May 22, 2024. Scotiabank started tracking with a Sector Outperform rating for this stock on February 08, 2024, and assigned it a price target of $80. In a note dated February 02, 2024, Stifel downgraded an Hold rating on this stock but restated the target price of $65.
The stock price of Bio-Techne Corp [TECH] has been fluctuating between $46.01 and $83.62 over the past year. Currently, Wall Street analysts expect the stock to reach $75 within the next 12 months. Bio-Techne Corp [NASDAQ: TECH] shares were valued at $49.85 at the most recent close of the market. An investor can expect a potential return of 50.45% based on the average TECH price forecast.
Analyzing the TECH fundamentals
The Bio-Techne Corp [NASDAQ:TECH] reported sales of 1.21B for trailing twelve months, representing a surge of 4.20%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.13%, and Net Profit Margin reading is 0.11%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.06 and Total Capital is 0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Bio-Techne Corp [NASDAQ:TECH]’s Current Ratio is 3.71. Also, the Quick Ratio is 2.58, while the Cash Ratio stands at 0.83. Considering the valuation of this stock, the price to sales ratio is 6.47, the price to book ratio is 3.87 and price to earnings (TTM) ratio is 60.76.
Transactions by insiders
Recent insider trading involved Herr Amy E., Director, that happened on Feb 14 ’25 when 1860.0 shares were sold. Domestic Partner of Director, JOSHUA MOLHO completed a deal on Feb 14 ’25 to buy 1860.0 shares. Meanwhile, Chief Executive Officer Kelderman Kim sold 13392.0 shares on Jan 27 ’25.
